Tetrahydrocannabinol potentiates reserpine-induced hypokinesia.                     (abst – 1981)




Loss of cannabinoid receptors in the substantia nigra in Huntington’s disease.









(abst – 1993)     


Cannabis in movement disorders.               (abst – 1999)


Cannabinoid Receptor Messenger Rna Levels Decrease in a Subset of Neurons of the Lateral Striatum, Cortex and Hippocampus of Transgenic Huntington’s Disease Mice. (abst – 2000)


Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington’s disease.      (abst – 2001)                             


Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington’s disease.                                                                  (abst – 2002)


Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington’s disease.                                             (abst – 2002)


Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington’s disease.                                                                (abst – 2003)


Effects of cannabinoids in the rat model of Huntington’s disease generated by an intrastriatal injection of malonate.                                                                      (abst – 2003)


The endocannabinoid system and Huntington’s disease.              (abst – 2003)


Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington’s disease transgenic mice.                                                                   (full – 2004)


Delayed onset of Huntington’s disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors.                                       (abst – 2004)


Cannabinoid control of motor function at the basal ganglia.               (abst – 2005)


Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington’s disease mice.      (abst – 2005)             


Nabilone Could Treat Chorea and Irritability in Huntington’s Disease              (letter – 2006)










UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington’s disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.                                                                                              (abst – 2006)


Cannabinoids and neuroprotection in motor-related disorders.              (abst – 2007)


Altered Lipid Metabolism in Brain Injury and Disorders                 (full – 2008)


The endocannabinoid system in Huntington’s disease.                (abst – 2008)


The endocannabinoid pathway in Huntington’s disease: a comparison with other neurodegenerative diseases.                                                           (abst – 2008)


Role of CB2 receptors in neuroprotective effects of cannabinoids.                (abst – 2008)


Microglial CB2 cannabinoid receptors are neuroprotective in Huntington’s disease excitotoxicity (full – 2009)                            


Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington’s disease.                                                             (abst – 2009)


The endocannabinoid system as a target for the treatment of motor dysfunction. (abst – 2009) nel.Pubmed_RVDocSum&ordinalpos=54


A pilot study using nabilone for symptomatic treatment in Huntington’s disease. (abst – 2009)   for_symptomatic_treatment_in_Huntington%27s_disease_


Cannabinoids and neurodegenerative diseases.                (abst – 2009)


Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington’s disease.                                                            (abst – 2009)


Medical Marijuana and Huntington’s Disease                (news – 2009)









Widespread Decrease of Type 1 Cannabinoid Receptor Availability in Huntington Disease In Vivo         (full – 2010)                      


Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.                                                            (full – 2010)


Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington’s disease. (full – 2010)                


Cannabinoids and Dementia: A Review of Clinical and Preclinical Data (link to PDF – 2010)                                     


The endocannabinoid system in gp120-mediated insults and HIV-associated dementia. (abst – 2010)                          


Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington’s disease transgenic mice.                                                                             (abst – 2010) nsequences_of_chronic_cannabinoid_treatment_in_Huntington%27s_disease_transgenic_mice_


Is lipid signaling through cannabinoid 2 receptors part of a protective system? (full – 2011)                        


Prospects for cannabinoid therapies in basal ganglia disorders.              (full – 2011)


Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease.   (full – 2011)                  


Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease.                                                    (abst – 2011)


Worsening of Huntington disease phenotype in CB1 receptor knockout mice. (abst – 2011)  ase_phenotype_in_CB1_receptor_knockout_mice_


Metabolic and Type 1 cannabinoid receptor imaging of a transgenic rat model in the early phase of Huntington disease                                                  (abst – 2011)  inoid_receptor_imaging_of_a_transgenic_rat_model_in_the_early_phase_of_Huntington_disease_


Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington’s disease.                                                          (abst – 2011)


Cannabinoid modulation of neuroinflammatory disorders.             (full – 2012)







The dynamic nature of type 1 cannabinoid receptor (CB1) gene transcription (full – 2012)                                  


Review article: The endocannabinoid system in normal and pathological brain ageing (abst – 2012)                                         


Cannabinoids: Novel Medicines for the Treatment of Huntington’s Disease. (abst – 2012)                               


Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?                                                    (abst – 2012)


Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington’s Disease: Role of CB(1) and CB(2) Receptors.        (abst – 2012)                            


Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington’s disease and mouse models.                                                               (abst – 2012)


Cannabinoid Receptor 2 Signaling in Peripheral Immune Cells Modulates Disease Onset and Severity in Mouse Models of Huntington’s Disease.                                                          (abst – 2012)


Share a link for